Login to Your Account

Pharma: Clinic Roundup

Wednesday, August 14, 2013
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., reported that USL255 (extended-release topiramate), an investigational once-daily formulation for the management of epilepsy, demonstrated equivalent systemic exposure with an improved topiramate's pharmacokinetic profile at steady-state, as measured by a significantly lower Cmax (p =/< 0.001) and higher Cmin (p =/< 0.001), when compared to immediate-release topiramate (TPM-IR) administered twice daily in healthy volunteers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription